ArticleIndian dermatology online journal
Growth Differentiation Factor-15: One of the Missing Links between Psoriasis and Metabolic Syndrome.
Article in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunomodulatory functions of growth differentiation factor 15 in skin aging and inflammatory dermatoses.Frontiers in immunology · 2026Review
- Psoriasis Comorbidities: Obesity, Diet, and Metabolic Syndrome.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic inflammatory condition of the skin that can be related to a variety of other conditions, including cardiovascular disease and metabolic syndrome. Growth differentiation factor-15 (GDF-15) is a cytokine that reacts to cellular stress. GDF-15 serum levels may have clinical uses in a variety of inflammatory and cardiovascular conditions. Objectives: To determine the levels of GDF-15 in the serum of patients with generalized plaque psoriasis (GPP) and its correlation with the metabolic syndrome. Patients and Methods: This case-control study included 50 patients with GPP and 50 age- and sex-matched healthy volunteers as controls. A general examination was performed, with a particular emphasis on measurements of body mass index, circumference of the waist, and blood pressure. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI) score. In addition, laboratory tests, including fasting blood sugar, lipid profile, and serum GDF-15 level measurement, were made. Results: Patients had significantly higher median GDF-15 levels compared to controls ( Limitation: The relatively small sample size could be a disadvantage and drawback of the study. Conclusion: Serum GDF-15 levels are linked to the severity of psoriasis and the associated metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.